HC Wainwright Has Bullish Forecast for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Stoke Therapeutics in a research note issued to investors on Tuesday, February 18th. HC Wainwright analyst A. Fein now expects that the company will earn ($2.68) per share for the year, up from their prior estimate of ($2.82). HC Wainwright currently has a “Buy” rating and a $47.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ FY2026 earnings at ($2.86) EPS, FY2027 earnings at ($1.65) EPS, FY2028 earnings at ($0.73) EPS and FY2029 earnings at $0.45 EPS.

STOK has been the subject of a number of other reports. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Chardan Capital restated a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics currently has a consensus rating of “Buy” and an average target price of $23.00.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $8.33 on Friday. Stoke Therapeutics has a 52 week low of $5.21 and a 52 week high of $17.58. The stock has a market capitalization of $441.24 million, a price-to-earnings ratio of -3.97 and a beta of 0.95. The stock has a fifty day moving average of $10.55 and a 200-day moving average of $12.29.

Insiders Place Their Bets

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 9,696 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $123,914.88. Following the completion of the sale, the general counsel now directly owns 35,142 shares in the company, valued at approximately $449,114.76. This trade represents a 21.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Barry Ticho sold 13,945 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $178,217.10. Following the sale, the insider now owns 47,332 shares of the company’s stock, valued at approximately $604,902.96. The trade was a 22.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,849 shares of company stock worth $809,421. Company insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in STOK. Toronto Dominion Bank bought a new position in shares of Stoke Therapeutics during the 4th quarter worth about $35,001,000. RTW Investments LP boosted its position in shares of Stoke Therapeutics by 10.1% during the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock worth $56,512,000 after purchasing an additional 471,240 shares in the last quarter. Norges Bank bought a new position in shares of Stoke Therapeutics during the 4th quarter worth about $3,472,000. Tang Capital Management LLC bought a new position in shares of Stoke Therapeutics during the 4th quarter worth about $3,309,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Stoke Therapeutics during the 4th quarter worth about $3,218,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.